Skip Navigation

European Heart Journal 1999 20(22):1657-1666; doi:10.1053/euhj.1999.1750
Copyright © 1999 by the European Society of Cardiology.
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Oldgren, J.
Right arrow Articles by Wallentin, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oldgren, J.
Right arrow Articles by Wallentin, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Activated partial thromboplastin time and clinical outcome after thrombin inhibition in unstable coronary artery disease

J. Oldgrena,f1, R. Linderb, L. Gripc, A. Siegbahnd and L. Wallentina

a Department of Cardiology, Uppsala University Hospital, Uppsala
d Department of Laboratory Medicine, Uppsala University Hospital, Uppsala
b Department of Cardiology, Karolinska Hospital, Stockholm
c Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden

revised June 15, 1999; accepted June 16, 1999

Abstract

Aims Direct thrombin inhibitors have failed to prove superiority over unfractionated heparin in several clinical trials of unstable coronary artery disease. We have investigated the relationship between activated partial thromboplastin time levels and adverse clinical events, i.e. death, myocardial (re-)infarction or refractory angina.

Methods and Results One thousand two hundred and nine patients with unstable coronary artery disease were randomized to 72h infusion with inogatran, a low molecular mass direct thrombin inhibitor, or unfractionated heparin. During 30 days follow-up there was no significant difference between inogatran and unfractionated heparin treatment as regards clinical outcome. 11·6% of the 464 inogatran treated patients with activated partial thromboplastin time above the median at 6h (44s) had a clinical event in 7 days, and 6·6% of the 423 patients with activated partial thromboplastin time below the median (P=0·01). After 30 days the event rate was still 41% higher in the inogatran patients with activated partial thromboplastin time above the median (P=0·06). Activated partial thromboplastin time in quartiles indicated a direct relationship between higher activated partial thromboplastin time and worse outcome. In contrast, during heparin infusion there was a trend for improved clinical outcome with activated partial thromboplastin time above the median, but this benefit was lost after cessation of treatment.

Conclusions Higher activated partial thromboplastin time levels during inogatran treatment are related to increased risk of death, myocardial infarction or refractory angina. This might, at least in part, be explained by differences in anticoagulant mechanisms between direct thrombin inhibitors and heparin, and further emphasizes the poorly defined optimal activated partial thromboplastin time range during treatment with direct thrombin inhibitors in unstable coronary artery disease.

Key Words: Anticoagulants, myocardial infarction, prognosis, thrombosis, unstable angina

f1 Correspondence: Jonas Oldgren, MD, Department of Cardiology, Uppsala University Hospital, S-751 85 Uppsala, Sweden.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur Heart JHome page
C. Christersson, J. Oldgren, A. Bylock, A. Siegbahn, and L. Wallentin
Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM trial
Eur. Heart J., March 2, 2007; 28(6): 692 - 698.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.